Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharma (NQ: SNDX )

14.52 -1.11 (-7.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,943,626
Open 15.79
Bid (Size) 16.72 (10)
Ask (Size) 16.73 (9)
Prev. Close 15.63
Today's Range 12.85 - 16.77
52wk Range 12.85 - 29.86
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga

Performance

YTD
-43.28%
-43.28%
1 Month
-25.73%
-25.73%
3 Month
-30.43%
-30.43%
6 Month
-30.56%
-30.56%
1 Year
-39.80%
-39.80%

More News

Read More
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Earnings Scheduled For August 3, 2023
Via Benzinga
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals
Via Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Via Benzinga
Syndax Pharmaceuticals Earnings Preview
Via Benzinga
Expert Ratings for Syndax Pharmaceuticals
Via Benzinga
Syndax Pharmaceuticals's Earnings: A Preview
Via Benzinga
Analyst Expectations for Syndax Pharmaceuticals's Future
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
Via Benzinga
Earnings Scheduled For May 8, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
Via Benzinga
Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
Via Benzinga
United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Earnings Scheduled For February 28, 2023
Via Benzinga
Earnings Scheduled For November 3, 2022
Via Benzinga
Earnings Preview For Syndax Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.